Skip to main content
Premium Trial:

Request an Annual Quote

Pyrosequencing Records Q3 Sales and Revenue Increase

SAN FRANCISCO, Oct. 24 – Pyrosequencing on Wednesday posted third-quarter revenues of $2.5 million compared to $1 million for the same quarter a year ago, the company announced.

The company credited an increase in sales of its PSQ 96 System and high throughput PTP systems for the revenue rise.

“We are pleased with our progress this quarter closing further sales of products based on our Pyrosequencing technology and achieving major advances in our molecular diagnostics business,” Erik Wallden, CEO of Pyrosequencing, said in a statement. “In addition to the more than 120 PSQ 96 Systems sold worldwide, we have sold several of our high-throughput systems.”

Pyrosequencing, based in Uppsala, Sweden, recorded a net loss of $2.4 million, or 7 cents per share, for the third quarter of 2001 compared to a loss of $800,000, or 3 cents per share, for the year-ago quarter. Operating expenses increased to $4.8 million for the third quarter of this year from $2.8 million in the same period in 2000.

As of September 30, 2001, Pyrosequencing had $65 million in cash and market securities.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.